Clinical Scorecard: Guiding Kidney-Sparing Approaches in Upper Tract Urothelial Carcinoma Through Liquid Biopsy: From Preoperative Risk Assessment to Perioperative Monitoring
At a Glance
Category
Detail
Condition
Key Mechanisms
Liquid biopsy for noninvasive detection and preoperative triage; ctDNA for biological upstaging.
Target Population
Care Setting
Urologic oncology clinics.
Key Highlights
Kidney-sparing surgery (KSS) is established for selected low-risk UTUC.
Liquid biopsy serves as an adjunct to traditional imaging and pathology.
Plasma ctDNA is linked to biological upstaging.
Guideline-Based Recommendations
Diagnosis
Utilize a combination of CTU, cytology, and ureteroscopy for diagnosis.
Management
KSS for low-risk localized UTUC; RNU for high-risk nonmetastatic disease.
Monitoring & Follow-up
Consider serial urinary or plasma tumor DNA for surveillance post-treatment.
Risks
Patient & Prescribing Data
Patients with low-risk localized UTUC.
Liquid biopsy can enhance decision-making for kidney preservation.
Clinical Best Practices
Integrate liquid biopsy results with traditional diagnostic methods.
Monitor patients postoperatively for molecular residual disease.
